Primary leiomyosarcoma of the skin

• Verfasst von: Zacher, Martina [VerfasserIn]
• Verfasst von: Heppt, Markus V. [VerfasserIn]
• Verfasst von: Brinker, Titus Josef [VerfasserIn]
• Verfasst von: Hayani, Kinan M. [VerfasserIn]
• Verfasst von: Flaig, Michael J. [VerfasserIn]
• Verfasst von: Berking, Carola [VerfasserIn]
• Titel: Primary leiomyosarcoma of the skin
• Titelzusatz: a comprehensive review on diagnosis and treatment
• Verf.angabe: Martina Zacher, Markus V. Heppt, Titus J. Brinker, Kinan M. Hayani, Michael J. Flaig, Carola Berking
• E-Jahr: 2018
• Jahr: 23 August 2018
• Umfang: 19 S.
• Fussnoten: Gesehen am 10.03.2020
• Titel Quelle: Enthalten in: Medical oncology
• Ort Quelle: New York, NY : Springer, 1984
• Jahr Quelle: 2018
• Band/Heft Quelle: Band 35.2018, Artikel-Nummer 135, 19 Seiten
• ISSN Quelle: 1559-131X
• DOI: doi:10.1007/s12032-018-1196-2
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1691958891

Abstract

Sarcomas are a heterogeneous group of mesenchymal tumors which can affect bone and soft tissue. Leiomyosarcoma (LMS) is a rare subtype localized to the skin or subcutaneous tissue. Due to the heterogeneity of sarcomas, reviews and guidelines with an in-depth focus specifically on primary LMS of the skin are sparse. This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists. We discuss novel treatment options for advanced disease such as targeted therapy with kinase inhibitors and immune checkpoint blockade which may improve the prognosis even in advanced stages of LMS.